{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:22:39Z","timestamp":1763202159975},"reference-count":165,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.arteri.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T12:33:21Z","timestamp":1525955601000},"page":"137-153","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diabetes mellitus y riesgo cardiovascular. Actualizaci\u00f3n de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Espa\u00f1ola de Diabetes (SED, 2018)"],"prefix":"10.1016","volume":"30","author":[{"given":"Francisco","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Obaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreu","family":"Nubiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo Fernando","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Mar","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Petrecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"S\u00e1nchez-Margalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Juan","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"T\u00e9bar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.arteri.2018.03.002_bib0850","first-page":"S1","article-title":"Standards of Medical Care in Diabetes \u2014 2018. ADA Clinical Practice Recommendations","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arteri.2018.03.002_bib0855","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.endonu.2013.11.005","volume":"61","author":"Arrieta","year":"2014","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.arteri.2018.03.002_bib0860","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.4067\/S0034-98872007001000008","article-title":"Gu\u00edas de pr\u00e1ctica cl\u00ednica en atenci\u00f3n primaria: Una evaluaci\u00f3n cr\u00edtica","volume":"135","author":"Pantoja","year":"2007","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.arteri.2018.03.002_bib0865","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Atherosclerotic cardiovascular disease and heart failure in type2 diabetes - Mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.03.002_bib0870","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1134-3230(11)70009-6","article-title":"Estudio descriptivo de la evoluci\u00f3n cl\u00ednico-asistencial de la poblaci\u00f3n con diabetes tipo2 en la Comunidad de Madrid. Estudio de seguimiento diab\u00e9tico tipo2 (ESD2)","volume":"27","author":"Arrieta","year":"2011","journal-title":"Av Diabetol"},{"key":"10.1016\/j.arteri.2018.03.002_bib0875","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.endonu.2010.05.009","article-title":"Evaluaci\u00f3n del grado de consecuci\u00f3n de objetivos de control metab\u00f3lico en pacientes con diabetes mellitus de tipo2","volume":"57","author":"Roca-Rodr\u00edguez","year":"2010","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib0880","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.endonu.2010.03.001","article-title":"Diabetes Mellitus and cardiovascular risk. Recommendations of the Working Group of Diabetes Mellitus and Cardiovascular Disease of the Spanish Diabetes Society 2009","volume":"57","year":"2010","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib0885","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.aprim.2015.05.002","article-title":"Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015)","volume":"48","author":"Arrieta","year":"2016","journal-title":"Aten Primaria"},{"key":"10.1016\/j.arteri.2018.03.002_bib0890","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.arteri.2014.12.003","article-title":"Diabetes mellitus and cardiovascular risk. Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015)","volume":"27","author":"Arrieta","year":"2015","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2018.03.002_bib0895","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type2 diabetes","volume":"34","author":"Wing","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arteri.2018.03.002_bib0900","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib0905","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study","volume":"22","year":"2014","journal-title":"Obesity (Silver Spring)."},{"key":"10.1016\/j.arteri.2018.03.002_bib0910","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3945\/ajcn.112.037853","article-title":"Malnutrition self-screening by using MUST in hospital outpatients: Validity, reliability, and ease of use","volume":"96","author":"Cawood","year":"2012","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib0915","first-page":"797","article-title":"Nutritional screening; control of clinical undernutrition with analytical parameters","volume":"29","author":"de Ul\u00edbarri P\u00e9rez","year":"2014","journal-title":"Nutr Hosp."},{"key":"10.1016\/j.arteri.2018.03.002_bib0920","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2018.03.002_bib0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-1725","article-title":"Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial","volume":"160","author":"Salas-Salvad\u00f3","year":"2014","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib0930","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0007114516002099","article-title":"Association between dietary fibre intake and fruit, vegetable or whole-grain consumption and the risk of CVD: Results from the PREvenci\u00f3n con DIeta MEDiterr\u00e1nea (PREDIMED) trial","volume":"116","author":"Buil-Cosiales","year":"2016","journal-title":"Br J Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib0935","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.atherosclerosis.2017.06.922","article-title":"The impact of serum trans fatty acids concentration on plaque vulnerability in patients with coronary artery disease: Assessment via optical coherence tomography","volume":"265","author":"Nagasawa","year":"2017","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2018.03.002_bib0940","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3945\/ajcn.112.041467","article-title":"Is there a dose-response relation of dietary glycemic load to risk of type2 diabetes? Meta-analysis of prospective cohort studies","volume":"97","author":"Livesey","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.arteri.2018.03.002_bib0945","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/aje\/kwt178","article-title":"Dietary carbohydrates, refined grains, glycemic load, and risk of coronary heart disease in Chinese adults","volume":"178","author":"Yu","year":"2013","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib0950","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4239\/wjd.v7.i7.142","article-title":"Novel nutraceutic therapies for the treatment of metabolic syndrome","volume":"7","author":"Mart\u00ednez-Abundis","year":"2016","journal-title":"World J Diabetes."},{"key":"10.1016\/j.arteri.2018.03.002_bib0955","first-page":"1","article-title":"A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors","volume":"11","author":"Dahlberg","year":"2017","journal-title":"Can J Physiol Pharmacol."},{"key":"10.1016\/j.arteri.2018.03.002_bib0960","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071498","article-title":"Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: Results from a randomized, double blind. placebo-controlled study","volume":"18","author":"Spigoni","year":"2017","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.arteri.2018.03.002_bib0965","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1017\/S0007114516004530","article-title":"Effect of dietary cholesterol and plant sterol consumption on plasma lipid responsiveness and cholesterol trafficking in healthy individuals","volume":"117","author":"Alphonse","year":"2017","journal-title":"Br J Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib0970","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clnesp.2016.06.004","article-title":"Association of dietary factors with severity of coronary artery disease","volume":"15","author":"Mahalle","year":"2016","journal-title":"Clin Nutr ESPEN."},{"key":"10.1016\/j.arteri.2018.03.002_bib0975","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIR.0b013e31829b5b44","article-title":"Exercise standards for testing and training: a scientific statement from the American Heart Association","volume":"128","author":"Fletcher","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2018.03.002_bib0980","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.recesp.2014.04.007","article-title":"Ejercicio f\u00edsico y salud","volume":"67","author":"Cordero","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib0985","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(12)61031-9","article-title":"Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy","volume":"380","author":"Lee","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2018.03.002_bib0990","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.107.185650","article-title":"Physical activity and public health in older adults: Recommendation from the American College of Sports Medicine and the American Heart Association","volume":"116","author":"Nelson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.03.002_bib0995","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-147-6-200709180-00005","article-title":"Effects of aerobic training, resistance training, or both on glycemic control in type2 diabetes: A randomized trial","volume":"147","author":"Sigal","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1000","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2011.576","article-title":"Physical activity advice only or structured exercise training and association with HbA1c levels in type2 diabetes: A systematic review and meta-analysis","volume":"305","author":"Umpierrez","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.03.002_bib1005","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/dme.13448","article-title":"The prevalence of diabetes-specific emotional distress in people with type2 diabetes: A systematic review and meta-analysis","volume":"34","author":"Perrin","year":"2017","journal-title":"Diabet Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1010","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jdiacomp.2017.08.001","article-title":"Multimorbidity is associated with increased rates of depression in patients hospitalized with diabetes mellitus in the United States","volume":"31","author":"Chima","year":"2017","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.arteri.2018.03.002_bib1015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/dc13-0762","article-title":"Reductions in regimen distress are associated with improved management and glycemic control over time","volume":"37","author":"Hessler","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1020","doi-asserted-by":"crossref","first-page":"e016317","DOI":"10.1136\/bmjopen-2017-016317","article-title":"Assessing oral medication adherence among patients with type2 diabetes mellitus treated with polytherapy in a developed Asian community: A cross-sectional study","volume":"7","author":"Lee","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.arteri.2018.03.002_bib1030","doi-asserted-by":"crossref","first-page":"e0182625","DOI":"10.1371\/journal.pone.0182625","article-title":"Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease","volume":"12","author":"Jowett","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2018.03.002_bib1035","first-page":"1","article-title":"Interventions to improve the appropriate use of polypharmacy for older people","volume":"5","author":"Patterson","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arteri.2018.03.002_bib1040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jsps.2014.07.008","article-title":"An evolving role of clinical pharmacists in managing diabetes: Evidence from the literature","volume":"24","author":"Alhabib","year":"2016","journal-title":"Saudi Pharm J."},{"key":"10.1016\/j.arteri.2018.03.002_bib1045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11325-016-1428-7","article-title":"CPAP therapy for patients with sleep apnea and type2 diabetes mellitus improves control of blood pressure","volume":"21","author":"Lam","year":"2017","journal-title":"Sleep Breath."},{"key":"10.1016\/j.arteri.2018.03.002_bib1050","article-title":"Effect of continuous positive airway pressure on glucose metabolism in adults with type2 diabetes: A systematic review and meta-analysis of randomized controlled trials","author":"Zhu","year":"2017","journal-title":"Sleep Breath."},{"key":"10.1016\/j.arteri.2018.03.002_bib1055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.redox.2017.06.006","article-title":"Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is metformin a viable countermeasure?","volume":"13","author":"Kaisar","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tox.2016.07.020","article-title":"A decade of e-cigarettes: Limited research & unresolved safety concerns","volume":"365","author":"Kaisar","year":"2016","journal-title":"Toxicology."},{"key":"10.1016\/j.arteri.2018.03.002_bib1065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijcard.2011.12.100","article-title":"Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: Meta-analysis of observational prospective studies","volume":"167","author":"Qin","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1070","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.je.2016.12.017","article-title":"Smoking and the risk of type2 diabetes in Japan: A systematic review and meta-analysis","volume":"27","author":"Akter","year":"2017","journal-title":"J Epidemiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2337\/dc11-1193","article-title":"Associations among visceral fat, all-cause mortality, and obesity-related mortality in Japanese Americans","volume":"35","author":"McNeely","year":"2012","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1080","first-page":"1480","article-title":"Influencia de la p\u00e9rdida de peso en la evoluci\u00f3n cl\u00ednica, metab\u00f3lica y psicol\u00f3gica de los pacientes con sobrepeso u obesidad","volume":"27","author":"Pi\u00f1era","year":"2012","journal-title":"Nutr Hosp."},{"key":"10.1016\/j.arteri.2018.03.002_bib1085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2174\/1573399810666140616144141","article-title":"Bariatric surgery \u2014 Effects on obesity and related co-morbidities","volume":"10","author":"Svane","year":"2014","journal-title":"Curr Diabetes Rev."},{"key":"10.1016\/j.arteri.2018.03.002_bib1090","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/ijo.2013.24","article-title":"Pharmaceutical utilisation and costs before and after bariatric surgery","volume":"37","author":"Keating","year":"2013","journal-title":"Int J Obes (Lond)."},{"key":"10.1016\/j.arteri.2018.03.002_bib1095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.endonu.2013.10.002","article-title":"Posicionamiento de las sociedades SEEN-SECO-SEEDO-SED sobre la cirug\u00eda metab\u00f3lica en la diabetes mellitus tipo-2","volume":"60","author":"Rubio","year":"2013","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.arteri.2018.03.002_bib1100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11695-015-1865-6","article-title":"Efficacy of bariatric surgery in type2 diabetes mellitus remission: The role of mini gastric bypass\/one anastomosis gastric bypass and sleeve gastrectomy at 1year of follow-up. A European survey","volume":"26","author":"Musella","year":"2016","journal-title":"Obes Surg."},{"key":"10.1016\/j.arteri.2018.03.002_bib1105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11695-013-1112-y","article-title":"Efficacy of metabolic surgery on HbA1c decrease in type2 diabetes mellitus patients with BMI <35kg\/m2\u2014a review","volume":"24","author":"Ngiam","year":"2014","journal-title":"Obes Surg."},{"key":"10.1016\/j.arteri.2018.03.002_bib1110","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s11695-014-1282-2","article-title":"Impact of different criteria on type2 diabetes remission rate after bariatric surgery","volume":"24","author":"Mas-Lorenzo","year":"2014","journal-title":"Obes Surg."},{"key":"10.1016\/j.arteri.2018.03.002_bib1115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patientes with type2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2018.03.002_bib1120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial interventions and cardiovascular disease in patients with type2 diabetes","volume":"348","author":"Gaude","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2018.03.002_bib1125","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"10.1016\/j.arteri.2018.03.002_bib1130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4158\/EP.12.S1.89","article-title":"Glycemic control and prevention of microvascular and macrovascular disease in the Steno2 study","volume":"12","author":"Vaag","year":"2006","journal-title":"Endocr Pract."},{"key":"10.1016\/j.arteri.2018.03.002_bib1135","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/jgs.12514","article-title":"American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update","volume":"61","author":"Moreno","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.arteri.2018.03.002_bib1140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4140\/TCP.n.2017.42","article-title":"Review of the next generation of long-acting basal insulins: Insulin Degludec and insulin Glargine","volume":"32","author":"Stailey","year":"2017","journal-title":"Consult Pharm."},{"key":"10.1016\/j.arteri.2018.03.002_bib1150","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1155","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1160","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2018.03.002_bib1695","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-016-0456-8","article-title":"Current perspectives on cardiovascular outcome trials in diabetes","volume":"15","author":"Schnell","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1700","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type2 (SGLT2) inhibitors for the treatment of type2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs."},{"key":"10.1016\/j.arteri.2018.03.002_bib1705","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.arteri.2018.03.002_bib1710","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1715","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1720","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40262-016-0498-9","article-title":"Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type2 diabetes","volume":"56","author":"Scheen","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.arteri.2018.03.002_bib1725","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jdiacomp.2016.08.017","article-title":"Following the LEADER \u2014 why this and other recent trials signal a major paradigm shift in the management of type2 diabetes","volume":"31","author":"Kosiborod","year":"2017","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.arteri.2018.03.002_bib1730","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/07853890.2017.1335428","article-title":"A review on cardiovascular effects of newer hypoglycaemic medications","volume":"49","author":"Cutshall","year":"2017","journal-title":"Ann Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1735","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1740","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1745","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1750","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1755","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(15)60037-X","article-title":"DPP-4 inhibitors and risk of heart failure EXAMINEd","volume":"385","author":"Standl","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.03.002_bib1760","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","article-title":"DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition","volume":"116","author":"Zhong","year":"2015","journal-title":"Circ Res."},{"key":"10.1016\/j.arteri.2018.03.002_bib1765","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1770","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet."},{"issue":"6 Suppl","key":"10.1016\/j.arteri.2018.03.002_bib1775","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2017.04.008","article-title":"Cardiovascular protection in the treatment of type2 diabetes: A review of clinical trial results across drug classes","volume":"130","author":"Paneni","year":"2017","journal-title":"Am J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1780","doi-asserted-by":"crossref","unstructured":"Carey RM, Whelton PK.The 2017 American College of Cardiology\/American Heart Association Hypertension Guideline: A Resource for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the Practicing Clinicians. Ann Intern Med. 2018;168(5):359-60.","DOI":"10.7326\/M18-0025"},{"key":"10.1016\/j.arteri.2018.03.002_bib1265","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: A position statement by the American Diabetes Association","volume":"40","author":"De Boer","year":"2017","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1270","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1038\/nutd.2013.32","article-title":"Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type2 diabetes mellitus: The SEARCH for diabetes in youth study","volume":"3","author":"Barnes","year":"2013","journal-title":"Nutr Diabetes."},{"key":"10.1016\/j.arteri.2018.03.002_bib1275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/01.HYP.0000202568.01167.B6","article-title":"Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association","volume":"47","author":"Appel","year":"2006","journal-title":"Hypertension."},{"key":"10.1016\/j.arteri.2018.03.002_bib1785","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2018.03.002_bib1280","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.03.002_bib1285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164114525548","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD \u2014 summary","volume":"11","author":"Ryd\u00e9n","year":"2014","journal-title":"Diab Vasc Dis Res."},{"issue":"Suppl 2","key":"10.1016\/j.arteri.2018.03.002_bib1290","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies\u2019 consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","year":"2014","journal-title":"Heart."},{"key":"10.1016\/j.arteri.2018.03.002_bib1295","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: Systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.arteri.2018.03.002_bib1300","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/HYPERTENSIONAHA.114.03958","article-title":"Targeting nocturnal hypertension in type2 diabetes mellitus","volume":"64","author":"Rossen","year":"2014","journal-title":"Hypertension."},{"key":"10.1016\/j.arteri.2018.03.002_bib1305","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"ESC Guidelines for the management of arterial hypertension; The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.arteri.2018.03.002_bib1310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/HJH.0b013e32835c5444","article-title":"Latin American consensus on hypertension in patients with diabetes type2 and metabolic syndrome","volume":"31","author":"Lopez-Jaramillo","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.arteri.2018.03.002_bib1315","first-page":"e93","article-title":"Adherence to antihypertensive medications among family practice patients with diabetes mellitus and hypertension","volume":"59","author":"Natarajan","year":"2013","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.arteri.2018.03.002_bib1320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18553\/jmcp.2016.22.1.63","article-title":"A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan","volume":"22","author":"Abughosh","year":"2016","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.arteri.2018.03.002_bib1325","article-title":"Fixed dose combination therapy to improve hypertension treatment and control in Latin America","author":"Gonz\u00e1lez-G\u00f3mez","year":"2017","journal-title":"Arch Cardiol Mex."},{"key":"10.1016\/j.arteri.2018.03.002_bib1330","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.03.002_bib1335","doi-asserted-by":"crossref","first-page":"h3978","DOI":"10.1136\/bmj.h3978","article-title":"Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type2 diabetes: Systematic review and meta-analysis of observational studies","volume":"351","author":"De Souza","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.arteri.2018.03.002_bib1340","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1345","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation."},{"issue":"25 Suppl 2","key":"10.1016\/j.arteri.2018.03.002_bib1350","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2018.03.002_bib1355","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arteri.2014.09.001","article-title":"Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management: Differences between the European and American Guidelines","volume":"27","author":"Lobos Bejarano","year":"2015","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2018.03.002_bib1360","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologist and American College of Endocrinology on the comprehensive type2 diabetes management algorithm-2017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocr Pract."},{"key":"10.1016\/j.arteri.2018.03.002_bib1365","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/eurheartj\/ehw377","article-title":"The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial","volume":"37","author":"Eisen","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.03.002_bib1370","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1375","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.recesp.2016.05.013","article-title":"Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posici\u00f3n de la Sociedad Espa\u00f1ola de Cardiolog\u00eda","volume":"69","author":"Anguita S\u00e1nchez","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1380","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J."},{"issue":"3 Suppl","key":"10.1016\/j.arteri.2018.03.002_bib1385","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1390","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4140\/TCP.n.2014.317","article-title":"Statin-associated incident diabetes: A literature review","volume":"29","author":"Park","year":"2014","journal-title":"Consult Pharm."},{"key":"10.1016\/j.arteri.2018.03.002_bib1395","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","article-title":"On treatment non-HDL cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: The JUPITER trial","volume":"59","author":"Mora","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1400","doi-asserted-by":"crossref","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.arteri.2018.03.002_bib1405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosissup.2017.05.030","article-title":"The efficacy of anti-PCSK9 antibodies: Results from recent trials","volume":"30","author":"Gouni-Berthold","year":"2017","journal-title":"Atheroscler Suppl."},{"key":"10.1016\/j.arteri.2018.03.002_bib1410","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1415","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1001\/jama.2015.14772","article-title":"Evolocumab (Repatha)\u2014a second PCSK9 inhibitor to lower LDL-cholesterol","volume":"314","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.03.002_bib1420","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.03.002_bib1425","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.amjcard.2017.06.023","article-title":"Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II)","volume":"120","author":"El Shahawy","year":"2017","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1430","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.diabet.2017.01.004","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type1 or type2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.arteri.2018.03.002_bib1445","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1900\/RDS.2013.10.171","article-title":"Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?","volume":"10","author":"Agouridis","year":"2013","journal-title":"Rev Diabet Stud."},{"key":"10.1016\/j.arteri.2018.03.002_bib1450","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(01)02147-6","article-title":"The relative role of low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol in coronary artery disease: Evidence from largescale statin and fibrate trials","volume":"88","author":"Sacks","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1455","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2018.03.002_bib1460","doi-asserted-by":"crossref","first-page":"e7671","DOI":"10.1097\/MD.0000000000007671","article-title":"Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients","volume":"96","author":"Ju","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.arteri.2018.03.002_bib1465","first-page":"300","article-title":"Reducing CV risk in diabetes: An ADA update","volume":"66","author":"Skolnik","year":"2017","journal-title":"J Fam Pract."},{"key":"10.1016\/j.arteri.2018.03.002_bib1470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/DMSO.S61438","article-title":"Importance of cardiovascular disease risk management in patients with type2 diabetes mellitus","volume":"23","author":"Lorber","year":"2014","journal-title":"Diabetes Metab Syndr Obes."},{"key":"10.1016\/j.arteri.2018.03.002_bib1475","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2337\/dc10-0555","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1480","doi-asserted-by":"crossref","first-page":"e001000","DOI":"10.1161\/JAHA.114.001000","article-title":"Circulating dickkopf-1 in diabetes mellitus: Association with platelet activation and effects of improved metabolic control and low-dose aspirin","volume":"3","author":"Lattanzio","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.arteri.2018.03.002_bib1485","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2018.03.002_bib1490","doi-asserted-by":"crossref","first-page":"e000651","DOI":"10.1136\/openhrt-2017-000651","article-title":"Dual antiplatelet therapy for secondary prevention of coronary artery disease","volume":"4","author":"Degrauwe","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.arteri.2018.03.002_bib1495","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","author":"Angiolillo","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2018.03.002_bib1500","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1505","doi-asserted-by":"crossref","first-page":"e0186961","DOI":"10.1371\/journal.pone.0186961","article-title":"Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome","volume":"12","author":"Patti","year":"2017","journal-title":"PLoS One."},{"issue":"Suppl 3","key":"10.1016\/j.arteri.2018.03.002_bib1510","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1262-3636(11)70962-4","article-title":"European Diabetes Working Party for Older People 2011 clinical guidelines for type2 diabetes mellitus. Executive summary","volume":"37","author":"Sinclair","year":"2011","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.arteri.2018.03.002_bib1515","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.clinthera.2013.07.427","article-title":"Management of acute coronary syndromes in patients with diabetes: Implications of the FREEDOM trial","volume":"35","author":"Burgess","year":"2013","journal-title":"Clin Ther."},{"key":"10.1016\/j.arteri.2018.03.002_bib1520","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1001\/jama.2013.281718","article-title":"Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: A systematic review","volume":"310","author":"Deb","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.03.002_bib1525","doi-asserted-by":"crossref","first-page":"e0177646","DOI":"10.1371\/journal.pone.0177646","article-title":"Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2018.03.002_bib1530","first-page":"9","article-title":"Recomendaciones sobre la detecci\u00f3n, seguimiento y criterios de derivaci\u00f3n de la enfermedad renal cr\u00f3nica en el \u00e1mbito de la Comunidad de Madrid","volume":"13","author":"Alc\u00e1zar","year":"2011","journal-title":"M\u00e9dicos de familia"},{"key":"10.1016\/j.arteri.2018.03.002_bib1535","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.arteri.2016.07.004","article-title":"Chronic kidney disease and dyslipidaemia","volume":"29","author":"Pascual","year":"2017","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2018.03.002_bib1540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of medical care in diabetes\u20142015 abridged for primary care providers","volume":"33","year":"2015","journal-title":"Clin Diabetes."},{"key":"10.1016\/j.arteri.2018.03.002_bib1545","first-page":"285","article-title":"Diabetes mellitus y enfermedad renal en el anciano","volume":"34","author":"Iglesias","year":"2014","journal-title":"Nefrologia."},{"key":"10.1016\/j.arteri.2018.03.002_bib1550","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2018.03.002_bib1555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hdi.12438","article-title":"systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease","volume":"21","author":"Kamiya","year":"2017","journal-title":"Hemodial Int."},{"key":"10.1016\/j.arteri.2018.03.002_bib1560","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4065\/mcp.2010.0713","article-title":"Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type2 diabetes mellitus","volume":"86","author":"Bakris GL:","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.arteri.2018.03.002_bib1565","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.03.002_bib1570","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2018.03.002_bib1575","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arteri.2018.03.002_bib1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2017.09.018","article-title":"Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia","author":"Chung","year":"2017","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2018.03.002_bib1585","first-page":"1","article-title":"Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia","volume":"4","author":"Davidson","year":"2014","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.arteri.2018.03.002_bib1590","series-title":"USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","year":"2013"},{"key":"10.1016\/j.arteri.2018.03.002_bib1595","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.medcli.2013.10.011","article-title":"Tratamiento de la diabetes tipo2 en el paciente anciano","volume":"142","author":"G\u00f3mez Huelgas","year":"2014","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.arteri.2018.03.002_bib1600","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(16)31213-2","article-title":"Mental illness: The forgotten burden on diabetes populations?","volume":"388","author":"Macdonald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2018.03.002_bib1605","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.2337\/dc16-2056","article-title":"Psychosocial research and care in diabetes: Altering lives by understanding attitudes","volume":"39","author":"Weinger","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arteri.2018.03.002_bib1610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12603-010-0001-5","article-title":"Effective clinical practice for older people with type2 diabetes. Glucose regulation is important but other strategies also need to be included","volume":"14","author":"Paolisso","year":"2010","journal-title":"J Nutr Health Aging."},{"key":"10.1016\/j.arteri.2018.03.002_bib1615","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1157\/13086204","article-title":"Prevalencia y consumo de medicaci\u00f3n en diabetes mellitus en la comunidad de Madrid","volume":"206","author":"Arrieta","year":"2006","journal-title":"Rev Clin Esp."},{"key":"10.1016\/j.arteri.2018.03.002_bib1620","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/jgs.12513","article-title":"Management of cardiovascular disease risk factors in older adults with type2 diabetes mellitus: 2002-2012 literature review","volume":"61","author":"Moreno","year":"2013","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.arteri.2018.03.002_bib1625","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/heartjnl-2013-304111","article-title":"Effects of antihypertensive treatment in patients over 65 years of age: A meta-analysis of randomised controlled studies","volume":"100","author":"Briasoulis","year":"2014","journal-title":"Heart."},{"key":"10.1016\/j.arteri.2018.03.002_bib1630","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2015.7517","article-title":"Polypharmacy in the aging patient: Management of hypertension in octogenarians","volume":"314","author":"Benetos","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.03.002_bib1635","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.arteri.2018.03.002_bib1640","doi-asserted-by":"crossref","DOI":"10.1007\/s11897-017-0371-7","article-title":"Treating disease mechanisms in patients with heart failure and diabetes mellitus","author":"Trang","year":"2017","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.arteri.2018.03.002_bib1645","article-title":"DPP-4 inhibitors and heart failure: A potential role for pharmacogenomics","author":"Krittanawong","year":"2017","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.arteri.2018.03.002_bib1650","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2016.02.146","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials","volume":"211","author":"Kongwatcharapong","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arteri.2018.03.002_bib1655","doi-asserted-by":"crossref","first-page":"e018097","DOI":"10.1136\/bmjopen-2017-018097","article-title":"Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): Protocol for a randomised controlled double-blind cross-over trial","volume":"7","author":"Mordi","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.arteri.2018.03.002_bib1660","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.03.002_bib1665","series-title":"Rehabilitaci\u00f3n cardiaca","first-page":"61","article-title":"Manejo pr\u00e1ctico de la obesidad en la enfermedad cardiovascular","author":"V\u00e1zquez Mart\u00ednez","year":"2009"},{"key":"10.1016\/j.arteri.2018.03.002_bib1670","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.2337\/db14-0956","article-title":"PTH-vitaminD-glycemia interactions reloaded","volume":"63","author":"Lee","year":"2014","journal-title":"Diabetes."},{"key":"10.1016\/j.arteri.2018.03.002_bib1675","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ecl.2017.07.009","article-title":"Role of vitaminD in cardiovascular diseases","volume":"46","author":"Rai","year":"2017","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.1016\/j.arteri.2018.03.002_bib1680","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13578-017-0183-1","article-title":"Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and prebiotics","volume":"7","author":"He","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.arteri.2018.03.002_bib1685","first-page":"32","article-title":"Diabetes y vitamina B12: una relaci\u00f3n de riesgo","volume":"1","author":"Llanes","year":"2014","journal-title":"Diabetes News."},{"key":"10.1016\/j.arteri.2018.03.002_bib1690","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.recesp.2017.02.034","article-title":"Basic concepts in molecular biology related to genetics and epigenetics","volume":"70","author":"Corella","year":"2017","journal-title":"Rev Esp Cardiol."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T21:26:39Z","timestamp":1571347599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916818300330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":165,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0214916818300330"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2018.03.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes mellitus y riesgo cardiovascular. Actualizaci\u00f3n de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Espa\u00f1ola de Diabetes (SED, 2018)","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}